TARO - Taro Pharmaceutical Industries Ltd.

NYSE - NYSE Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
3.32B
Enterprise Value 3
2.25B
Trailing P/E
12.06
Forward P/E 1
10.69
PEG Ratio (5 yr expected) 1
-1.03
Price/Sales (ttm)
4.89
Price/Book (mrq)
1.63
Enterprise Value/Revenue 3
3.31
Enterprise Value/EBITDA 6
7.34

Trading Information

Stock Price History

Beta (5Y Monthly) 0.67
52-Week Change 3-6.55%
S&P500 52-Week Change 325.98%
52 Week High 3109.42
52 Week Low 372.97
50-Day Moving Average 390.51
200-Day Moving Average 383.03

Share Statistics

Avg Vol (3 month) 379.84k
Avg Vol (10 day) 355.57k
Shares Outstanding 538.54M
Float 8.82M
% Held by Insiders 177.10%
% Held by Institutions 111.62%
Shares Short (Dec 30, 2019) 4205.93k
Short Ratio (Dec 30, 2019) 42.15
Short % of Float (Dec 30, 2019) 4N/A
Short % of Shares Outstanding (Dec 30, 2019) 40.42%
Shares Short (prior month Nov 28, 2019) 4297.44k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Dec 27, 2018
Ex-Dividend Date 4Dec 09, 2018
Last Split Factor 22:1
Last Split Date 3Jul 26, 2001

Financial Highlights

Fiscal Year

Fiscal Year Ends Mar 30, 2019
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 40.43%
Operating Margin (ttm)42.10%

Management Effectiveness

Return on Assets (ttm)7.43%
Return on Equity (ttm)12.54%

Income Statement

Revenue (ttm)678.45M
Revenue Per Share (ttm)17.56
Quarterly Revenue Growth (yoy)1.20%
Gross Profit (ttm)445.72M
EBITDA 306.05M
Net Income Avi to Common (ttm)274.3M
Diluted EPS (ttm)7.09
Quarterly Earnings Growth (yoy)-10.20%

Balance Sheet

Total Cash (mrq)1.06B
Total Cash Per Share (mrq)27.44
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)7.06
Book Value Per Share (mrq)52.56

Cash Flow Statement

Operating Cash Flow (ttm)289.42M
Levered Free Cash Flow (ttm)194.56M